Abbott (ABT) Q1 2025: Margin Expansion and Diversified Growth Offset Tariff Uncertainty

April 16, 2025 | By EarningsIQ Research

Abbott delivered robust high single-digit organic sales growth and double-digit EPS expansion in Q1 2025, demonstrating operational resilience across its diversified healthcare portfolio. Margin gains and strong execution in medical devices and nutrition offset headwinds in diagnostics and looming tariff impacts, with management reaffirming full-year guidance and emphasizing sustainable mitigation strategies.

Summary

• Margin Expansion Outpaces Expectations: Gross margin rose 140 basis points YoY, fueling 11% EPS growth despite currency and tariff pressures.
• Medical Devices and Nutrition Drive Top-Line: Medical devices grew 12.5%, led by diabetes and structural heart, while nutrition posted 7% growth.
• Tariff Mitigation in Focus: Management estimates a few hundred million dollar tariff impact in 2025 but points to global manufacturing flexibility and multi-year mitigation levers.
• Diagnostics Lags, China Headwind Persists: Diagnostics fell 5% due to weak COVID testing and China price pressure, but ex-China core lab sales grew 6.5%.

Performance Analysis

Abbott posted Q1 sales growth of 7% (8% ex-COVID testing), with adjusted EPS of $1.09 up 11% YoY and at the high end of guidance. Margin discipline stood out, with gross margin climbing 140 basis points to 61.1% and operating margin expanding 130 basis points to 21%.

Medical devices, a 12.5% growth engine, contributed outsized gains, powered by continuous glucose monitors (CGM, diabetes care segment, $1.7B sales, up 20%+), electrophysiology, and structural heart. Nutrition, spanning pediatric and adult brands like Similac and Ensure, grew 7% on US pediatric and adult demand. Diagnostics sales fell 5% as COVID testing declined sharply and core lab growth in China was pressured by volume-based procurement (VBP) pricing. Excluding China, core lab sales grew 6.5%.

• Device Segment Momentum: Diabetes, electrophysiology, and structural heart all posted double-digit growth, with new product launches and clinical data fueling pipeline confidence.
• Diagnostics Drag: COVID testing fell off, and China VBP price cuts led to no volume offset, uniquely impacting Abbott versus prior cycles.
• Gross Margin Leverage: Margin improvement initiatives, supply chain optimization, and FX tailwinds contributed to stronger-than-expected profitability.

Despite macro and tariff headwinds, Abbott’s diversified model and disciplined cost management underpinned another quarter of reliable growth and margin expansion.

Executive Commentary

Strategic Positioning

1. Diversified Global Manufacturing as Tariff Shield

Abbott’s 90-site global manufacturing network enables agile response to tariffs and supply shocks. The company’s longstanding strategy of aligning production close to demand and maintaining redundancy provides natural hedges against FX and trade disruption, especially for high-growth franchises like Libre (CGM, six global sites, two in US).

2. Medical Devices as Growth Engine

Devices led by diabetes (Libre CGM), electrophysiology (Volt PFA), and structural heart (Triclip, Navitor) are Abbott’s primary organic growth lever. New launches, clinical data, and expanded indications are expected to accelerate second-half growth, with Volt PFA’s European approval and US submission on track.

3. Diagnostics Repositioning and M&A Discipline

Diagnostics faces headwinds in China due to VBP price cuts without volume offsets. Abbott is investing in new platforms (Alinity N for nucleic acid testing, $1B market opportunity) and remains open to M&A, but management stresses financial discipline and prioritizes organic growth and margin expansion.

4. Margin Expansion as Core Pillar

Margin improvement is embedded in Abbott’s operating model, with ongoing initiatives across supply chain, R&D, and SG&A. This discipline is critical for offsetting tariff and FX headwinds, sustaining EPS growth, and protecting capital allocation flexibility.

5. Balanced Capital Allocation and Portfolio Review

Abbott continues to review its portfolio for value unlocks but sees its diversified model as a strategic advantage, not a breakup candidate. Capital deployment remains focused on high-return organic and select inorganic investments, with no change in M&A appetite or priorities.

Key Considerations

Abbott’s Q1 results highlight the company’s ability to deliver consistent growth and margin expansion even amid external volatility. The following considerations frame the strategic context for investors:

Key Considerations:

• Tariff Impact Timing and Mitigation: Tariffs are expected to cost a few hundred million dollars in 2025 (half-year effect), with mitigation relying on manufacturing shifts, FX, and other levers rather than R&D or SG&A cuts.
• Device Pipeline Execution: Medical device launches (Volt PFA, new Triclip, IVL system) are critical to sustaining above-market growth and offsetting slower segments.
• Diagnostics China Headwind: VBP-driven price declines in China are unique in lacking volume offsets, requiring strategic focus on ex-China growth and new product innovation.
• Margin Discipline as Strategic Lever: Ongoing gross and operating margin expansion is a differentiator, providing resilience against macro and regulatory shocks.
• Capital Allocation Flexibility: Abbott’s strong balance sheet and disciplined approach to M&A and portfolio management enable opportunistic investment without sacrificing profitability.

Risks

Tariff escalation remains a key risk, with management warning against simply annualizing the 2025 impact due to mitigation plans. Diagnostics faces persistent price pressure in China, and device launches must deliver to sustain growth. Regulatory, FX, and macro volatility could further pressure margins, while portfolio complexity increases execution risk.

Forward Outlook

For Q2 2025, Abbott guided to:

• Adjusted EPS of $1.23 to $1.27
• Organic sales growth in the high single digits (excluding COVID testing)
• Gross margin expansion to continue, though tariffs will begin to impact in Q3

For full-year 2025, management reaffirmed guidance:

• Double-digit adjusted EPS growth
• High single-digit organic sales growth
• Tariff headwind estimated at a few hundred million dollars (half-year effect)

Management highlighted:

• Second-half acceleration from new device launches and easier comps in diagnostics and nutrition
• Ongoing gross and operating margin expansion as a buffer against external shocks
• No planned cuts to R&D or SG&A as part of tariff mitigation

Takeaways

Abbott’s diversified model and operational discipline underpinned another quarter of reliable growth, with medical devices and margin gains offsetting diagnostics weakness and tariff uncertainty.

• Margin Expansion Drives EPS: Gross margin gains and disciplined cost control were central to double-digit EPS growth, reinforcing Abbott’s resilience.
• Device Pipeline Critical: Sustained execution in diabetes, structural heart, and electrophysiology is needed to maintain top-tier growth and offset segment headwinds.
• Tariff Mitigation in Progress: Investors should monitor Abbott’s ability to execute long-term manufacturing shifts and supply chain adjustments to contain tariff impact in 2026 and beyond.

Conclusion

Abbott’s Q1 2025 results underscore the value of a diversified healthcare platform, with strong margin execution and device-led growth offsetting external shocks. The company’s proactive tariff mitigation and disciplined capital allocation position it well for continued resilience, but device pipeline delivery and China diagnostics remain watchpoints.

Read-Through

Abbott’s results reinforce the strategic value of global manufacturing diversification and operational flexibility in a volatile trade and regulatory landscape. For medtech peers, the ability to shift production and maintain margin discipline will be critical as tariffs and price controls proliferate. Diagnostics players face a new normal in China, where price pressure may not be offset by volume, while device innovators must deliver pipeline execution to sustain above-market growth. The broader healthcare sector should expect continued emphasis on cost control and supply chain optimization as macro and policy headwinds persist.

ABT Healthcare Medical Devices Diagnostics Margin Expansion Tariffs Supply Chain Pipeline